In vitro synergism of simvastatin and fluconazole against Candida species;Sinergismo in vitro de sinvastatina e fluconazol contra espécies de Candida

Revista do Instituto de Medicina Tropical de Sao Paulo

Volumn 54, Issue 4, 2012, Pages 197-199

  Menezes, Everardo Albuquerque ^a   de Vasconcelos, Antônio Alexandre ^a   Silva, Carlla Lorena Façanha ^a   Plutarco, Fábio Ximenes ^a   Cunha, Maria da Conceição dos Santos Oliveira ^a   Cunha, Francisco Afrânio ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Candida spp; Fluconazole; Simvastatin

Indexed keywords

FLUCONAZOLE; SIMVASTATIN;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; FRACTIONAL INHIBITORY CONCENTRATION INDEX; FUNGAL STRAIN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACOLOGICAL PARAMETERS;

EID: 84864987868     PISSN: 00364665     EISSN: 16789946     Source Type: Journal    
DOI: 10.1590/S0036-46652012000400003     Document Type: Article

References (12)

1. Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care. 2010;16:445-52.
2. Clinical and Laboratory Standards Institute. (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts. Wayne: Clinical and Laboratory Standards Institute; 2008. Supplement M27-A3.
3. Forrest GN, Kopack AM, Perencevich EN. Research article statins in Candidemia: clinical outcomes from a matched cohort study. BMC Infect Dis. 2010;10:152-9.
4. Lass-Flörl C, Perkhofer S, Mayr A. In vitro susceptibility testing in fungi: a global perspective on a variety of methods. Mycoses. 2010;53:1-11
5. Lefebvre M, Alshawa K, Dupont B. L'activité antifongique des statines. J Mycol Med. 2010;20:212-7.
6. Liu G, Vellucci VF, Kyc S. Hostetter MK. Simvastatin inhibits Candida albicans biofilm in vitro. Pediat Res. 2009;66:600-4.
7. Macreadie IG, Johnson G, Schlosser T, Macreadie PI. Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol Lett. 2006;262:9-13.
8. Meletiadis J, Pournaras S, Roilides E, Walsh TJ. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob Agents Chemother. 2010;54:602-9.
9. Nyilasi I, Kocsubé S, Krizsán K, Galgóczy L, Pesti M, Papp T, et al. In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi. FEMS Microbiol Lett. 2010;307:175-84.
10. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52:1.
11. Vasconcelos Jr AA, Menezes EA, Cunha, FA. Chromogenic medium for direct susceptibility testing of Candida spp. isolated from urine. Mycopathologia. 2011;172:125-30.
12. Wikhe K, Westermeyer C, Macreadie IG. Biological consequences of statins in Candida species and possible implications for human health. Biochem Soc Trans. 2007;35:1529-32.